Pharsight

1. List of Picato drug patents

Application	Filing Date	Opposition Party	Legal Status
EP06820561A	2014-11-12	Actavis PTC ehf	Revoked
EP06820561A	2014-11-12	Galenicum Health S.L.	Revoked
EP06820561A	2014-11-11	Sandoz AG	Revoked

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9833428	LEO LABS	Therapeutic compositions	Dec, 2026 (3 years from now)
US8716271	LEO LABS	Therapeutic compositions	Dec, 2026 (3 years from now)
US9820959	LEO LABS	Therapeutic compositions	Dec, 2026 (3 years from now)
US8735375	LEO LABS	Therapeutic compositions	Dec, 2026 (3 years from now)
US9861603	LEO LABS	Therapeutic compositions	Dec, 2026 (3 years from now)
US8372828	LEO LABS	Therapeutic compositions	Dec, 2026 (3 years from now)
US8536163	LEO LABS	Therapeutic compositions	Dec, 2026 (3 years from now)
US8372827	LEO LABS	Therapeutic compositions	Dec, 2026 (3 years from now)
US8377919	LEO LABS	Therapeutic compositions	Dec, 2026 (3 years from now)
US9833429	LEO LABS	Therapeutic compositions	Dec, 2026 (3 years from now)
US8278292	LEO LABS	Therapeutic compositions	Jul, 2027 (4 years from now)
US9789078	LEO LABS	Method of topically treating actinic keratosis with ingenol mebutate cycle therapy	May, 2033 (9 years from now)

Do you want to check out PICATO patents from before 2022?

Drugs and Companies using INGENOL MEBUTATE ingredient

Market Authorisation Date: 23 January, 2012

Treatment: Use of ingenol mebutate to treat actinic keratosis; Topical treatment of actinic keratosis of the face or scalp using more than one treatment course of ingenol mebutate

Dosage: GEL;TOPICAL